Constipation, somewhat counterintuitively for a GLP-1 agonist, occurred in 5-7%
There is evidence that IGF-I and its receptor are expressed in the myocardium and both aortic smooth muscle and endothelial cells[45, 147149], being all of them more sensitive to IGF-I than to insulin[150, 151]
Gastrointestinal effects are the most frequently reported side effects and include: Nausea (1224% of patients): Often most pronounced during treatment initiation and dose escalation, typically improving over time Diarrhea (1323% of patients): May be transient or persistent, requiring dietary modifications Vomiting (611% of patients): Can lead to dehydration if severe or prolonged Constipation (617% of patients): May require increased fiber intake and hydration Abdominal pain or discomfort (610% of patients): Usually mild to moderate in severity Decreased appetite : Therapeutic effect but may be excessive in some individuals These gastrointestinal symptoms generally diminish over several weeks as the body adjusts to the medication
Both GHRH analogs and ghrelin mimetics were previously employed in our laboratory studies to evaluate pulsatile secretion of a particular hormone and its receptor interaction, and used together they helped to explore mechanisms related to them more broadly than did use of any single compounds in the research that were found within a database in PubMed
It is administered via subcutaneous injection, though oral formulations are also being studied
The April 2026 FDA reclassification has made legitimate access through licensed clinicians and compliant compounding pharmacies more straightforward than it has been in years
